UK becomes first European country to approve Eli Lilly's obesity pill
The UK has authorised Eli Lilly's oral drug Foundayo for weight loss and type 2 diabetes, a European first.
Britain has become the first country in Europe to approve Eli Lilly's oral medication Foundayo for weight management and the treatment of type 2 diabetes. The decision was announced on Monday by the UK's medicines regulator.
The authorisation marks a significant step for the pharmaceutical giant, expanding the availability of its weight-loss treatment beyond existing injectable options. Foundayo is designed to be taken as a pill, offering an alternative for patients seeking a less invasive approach to managing their condition.
The regulatory green light covers both weight management and type 2 diabetes, addressing two closely linked health concerns. While the approval is specific to the UK market, it could pave the way for similar decisions in other European nations.
Eli Lilly has not yet commented on the commercial launch timeline or pricing details for the UK market. The regulator's decision is based on clinical data demonstrating the drug's efficacy and safety profile for the approved indications.